


Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 084335/0120	SERIAL NO. 09/550,115
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Ken-ichi Arai et al.	
		FILING DATE April 14, 2000	GROUP ART UNIT 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A2	E. S. Masuda et al., Cell. Signal, "Signalling into the T-Cell Nucleus: NFAT Regulation," Vol. 10, No. 9, pp. 599-611 (1998)
	A3	E. s. Masuda et al., Molecular and Cellular Biology, "NFATx, a Novel Member of the Nuclear Factor of Activated T Cells Family That Is Expressed Predominantly in the Thymus," Vol. 15, No. 5, pp. 2697-2706 (1995)
	A4	E. s. Masuda et al., Molecular and Cellular Biology, "Control of NFATx1 Nuclear Translocation by a Calcineurin-Regulated Inhibitory Domain," Vol. 17, No. 4, pp. 2066-2075 (1997)
	A5	C. R. Beals et al., Genes & Development, "Nuclear localization of NF-Atc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction," Vol. 11, pp. 824-834 (1997)
	A6	J Liu et al., Molecular Biology of the Cell, "Calcineurin-dependent Nuclear Translocation of a Murin Transcription Factor NFATx: Molecular Cloning and Functional Characterization," Vol. 8, pp. 157-170 (1997)
	A7	J. Aramburu et al., Molecular Cell, "Selective Inhibition of NFAT Activation by a Peptide Spanning the Calcineurin Targeting Site of NFAT," Vol. 1, pp. 627-637 (1998)
	A8	J. Zhu et al., Cell, "Intramolecular Masking of Nuclear Import Signal on NF-AT4 by Casein Kinase I and MEKK1," Vol. 93, pp. 851-861 (1998)

EXAMINER


S. Mays

DATE CONSIDERED

4/21/03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: August 14, 2001

(use as many sheets as necessary)

Complete if Known

Application Number	09/550,115	RECEIVED AUG 15 2001 TECH CENTER 1600/2900
Filing Date	April 14, 2000	
First Named Inventor	Ken-ichi Arai	
Group Art Unit	1646	
Examiner Name	Hope Robinson	
Attorney Docket Number	084335-0120	

Sheet 1 of 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
fm		J. LIU et al., The Journal of Immunology, "Two Independent Calcineurin-Binding Regions in the N-Terminal Domain of Murine NF-ATx1 Recruit Calcineurin to Murine NF-ATx1, pp. 4755-4761 (1999) The American Association of Immunologists	

Examiner Signature

L. Hays

Date Considered

4/21/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.